IOVS Journal of Pharmacology and Experimental Therapeutics
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

(Investigative Ophthalmology and Visual Science. 2007;48:4399-4402.)
© 2007 by The Association for Research in Vision and Ophthalmology, Inc.
DOI:  10.1167/iovs.07-0552
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barak, V.
Right arrow Articles by Folberg, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barak, V.
Right arrow Articles by Folberg, R.

Using the Direct-Injection Model of Early Uveal Melanoma Hepatic Metastasis to Identify TPS as a Potentially Useful Serum Biomarker

Vivian Barak,1 Shahar Frenkel,2 Klara Valyi-Nagy,3 Lu Leach,3 Marsha A. Apushkin,3 Amy Y. Lin,3 Inna Kalickman,1 Nikola A. Baumann,3 Jacob Pe’er,2 Andrew J. Maniotis,3 and Robert Folberg3

1From the Immunology Laboratory for Tumor Diagnosis and the 2Department of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; and the 3Department of Pathology, University of Illinois at Chicago, Chicago, Illinois.

PURPOSE. To develop a method to screen for serum biomarkers of early hepatic metastasis from uveal melanoma.

METHODS. Cytokeratin 18 (TPS) was identified from gene expression profiles as protein generated by highly invasive uveal melanoma cells. Sera were collected from two groups of 15 SCID mice 2 weeks after injection of either tissue culture medium or MUM2B human metastatic uveal melanoma cells into the mouse liver. Serum TPS levels were assayed in 53 healthy human controls, 64 uveal melanoma patients who were disease free for at least 10 years, and 37 patients with metastatic uveal melanoma.

RESULTS. After 2 weeks, small hepatic nodules (0.1–2.8 mm; mean, 0.80 mm) developed in 11 of 15 mice injected with MUM2B cells. Serum TPS levels in media-injected mice (84.7 U/L) were substantially lower than levels in MUM2B-injected mice (601 µg/L). TPS levels were significantly higher (P < 0.0001) in patients with metastatic uveal melanoma (139.63 ± 22.20) than in healthy controls (54.23 ± 0.01) or in patients free of disease (69.29 ± 9.76). Significant differences were found between TPS levels before and after the development of hepatic metastases (P < 0.01), and serum TPS levels became elevated in four patients at least 6 months before the detection of hepatic metastases by abdominal ultrasonography.

CONCLUSIONS. The direct-injection model of uveal melanoma in the mouse liver may be used to screen for potential serum biomarkers of metastatic uveal melanoma.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the Association for Research in Vision and Ophthalmology